<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311895</url>
  </required_header>
  <id_info>
    <org_study_id>MMC 10-07-201</org_study_id>
    <nct_id>NCT01311895</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone</brief_title>
  <official_title>Randomized Clinical Trial Comparing Two Protocols Using IV Hydromorphone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two opioid protocols (&quot;H2O&quot; and &quot;1+1&quot;) for the
      treatment of acute severe pain in the emergency department. The investigators primary
      hypothesis is that the &quot;H2O&quot; protocol will be more efficacious than the &quot;1+1&quot; protocol in
      Emergency Department patients aged 21-64 years. The primary outcome is the proportion of
      patients in each arm who choose to forgo additional pain medication at 60 minutes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Satisfactory Pain Management at 60 Minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>The primary outcome is the proportion of patients in each arm who choose to forgo additional pain medication at 60 minutes. This is defined as the number of patients who declined additional pain medication at 60 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Pain Intensity From Baseline to 60 Minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>Pain intensity is measured in numerical rating scale (NRS) units from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). The change here represents the NRS score given by the patients at 60 minutes subtracted from the score at baseline, before treatment in the Emergency Department.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Reported no Pain or Mild Pain at 60 Minutes</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>H2O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg IV hydromorphone administered over 2-3 minutes as initial dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1+1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the following question: &quot;Do you want more pain medication?&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H2O</intervention_name>
    <description>2 mg IV hydromorphone</description>
    <arm_group_label>H2O</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1+1</intervention_name>
    <description>1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
    <arm_group_label>1+1</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than 21 years and less than 65 years: This is a study of non-elderly adult
             patients. In addition, patients aged 21 years and younger are automatically triaged to
             the Children's Emergency Department (ED).

          2. Pain with onset within 7 days: Pain within seven days is the definition of acute pain
             that has been used in ED literature.

          3. ED attending physician's judgment that patient's pain warrants intravenous (IV)
             opioids

        Exclusion Criteria:

          1. Use of other opioids or tramadol within past 24 hours: to avoid introducing assembly
             bias related to recent opioid use, since this may affect baseline levels of pain and
             need for analgesics.

          2. Prior adverse reaction to opioids.

          3. Chronic pain syndrome: frequently recurrent or daily pain for at least 3 months
             results in modulation of pain perception which is thought to be due to down-regulation
             of pain receptors. Examples of chronic pain syndromes include sickle cell anemia,
             osteoarthritis, fibromyalgia, and peripheral neuropathies.

          4. Alcohol intoxication: the presence of alcohol intoxication as judged by the treating
             physician may alter pain perception.

          5. Systolic Blood Pressure &lt;90 mm Hg: Opioids can produce peripheral vasodilation that
             may result in orthostatic hypotension.

          6. Oxygen saturation &lt; 95% on room air: For this study, oxygen saturation must be 95% or
             above on room air in order to be enrolled.

          7. Use of monoamine oxidase (MAO) inhibitors in past 30 days: MAO inhibitors have been
             reported to intensify the effects of at least one opioid drug causing anxiety,
             confusion and significant respiratory depression or coma.

          8. CO2 measurement greater than 46: In accordance with standard protocol, three subsets
             of patients will have their CO2 measured using a handheld capnometer prior to
             enrollment in the study. If the CO2 measurement is greater than 46 then the patient
             will be excluded from the study. The 3 subsets are as follows:

               -  All patients who have a history of chronic obstructive pulmonary disease (COPD)

               -  All patients who report a history of asthma together with greater than a 20
                  pack-year smoking history

               -  All patients reporting less than a 20 pack-year smoking history who are having an
                  asthma exacerbation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center Moses Division Emergency Department</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <results_first_submitted>February 27, 2017</results_first_submitted>
  <results_first_submitted_qc>April 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2018</results_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Chang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>acute</keyword>
  <keyword>pain</keyword>
  <keyword>emergency department</keyword>
  <keyword>hydromorphone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>H2O (2 mg IV Hydromorphone)</title>
          <description>2 mg IV hydromorphone
H2O: 2 mg intravenous (IV) hydromorphone</description>
        </group>
        <group group_id="P2">
          <title>1+1 (1 mg IV Hydromorphone + Optional 1 mg IV Hydromorphone)</title>
          <description>1 mg intravenous (IV) hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the following question: &quot;Do you want more pain medication?&quot;
1+1: 1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.
H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).
1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)</population>
      <group_list>
        <group group_id="B1">
          <title>H2O (2 mg IV Hydromorphone)</title>
          <description>2 mg IV hydromorphone
H2O: 2 mg IV hydromorphone</description>
        </group>
        <group group_id="B2">
          <title>1+1 (1 mg IV Hydromorphone + Optional 1 mg IV Hydromorphone)</title>
          <description>1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the following question: &quot;Do you want more pain medication?&quot;
1+1: 1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
            <count group_id="B2" value="168"/>
            <count group_id="B3" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="33" upper_limit="52"/>
                    <measurement group_id="B2" value="42" lower_limit="33" upper_limit="50"/>
                    <measurement group_id="B3" value="43" lower_limit="33" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180" lower_limit="165" upper_limit="210"/>
                    <measurement group_id="B2" value="186" lower_limit="170" upper_limit="219"/>
                    <measurement group_id="B3" value="184" lower_limit="165" upper_limit="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of pain</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain intensity</title>
          <description>Pain intensity is measured on the numerical rating scale (NRS) from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>3-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nauseated or vomited before receiving opioids in the Emergency Department (ED)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Satisfactory Pain Management at 60 Minutes</title>
        <description>The primary outcome is the proportion of patients in each arm who choose to forgo additional pain medication at 60 minutes. This is defined as the number of patients who declined additional pain medication at 60 minutes.</description>
        <time_frame>60 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.
H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).
1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)</population>
        <group_list>
          <group group_id="O1">
            <title>H2O (2 mg IV Hydromorphone)</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes as initial dose
H2O: 2 mg IV hydromorphone</description>
          </group>
          <group group_id="O2">
            <title>1+1 (1 mg IV Hydromorphone + Optional 1 mg IV Hydromorphone)</title>
            <description>1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the following question: &quot;Do you want more pain medication?&quot;
1+1: 1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Satisfactory Pain Management at 60 Minutes</title>
          <description>The primary outcome is the proportion of patients in each arm who choose to forgo additional pain medication at 60 minutes. This is defined as the number of patients who declined additional pain medication at 60 minutes.</description>
          <population>The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.
H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).
1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Pain Intensity From Baseline to 60 Minutes</title>
        <description>Pain intensity is measured in numerical rating scale (NRS) units from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). The change here represents the NRS score given by the patients at 60 minutes subtracted from the score at baseline, before treatment in the Emergency Department.</description>
        <time_frame>60 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.
H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).
1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)</population>
        <group_list>
          <group group_id="O1">
            <title>H2O (2 mg IV Hydromorphone)</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes as initial dose
H2O: 2 mg IV hydromorphone</description>
          </group>
          <group group_id="O2">
            <title>1+1 (1 mg IV Hydromorphone + Optional 1 mg IV Hydromorphone)</title>
            <description>1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the following question: &quot;Do you want more pain medication?&quot;
1+1: 1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Pain Intensity From Baseline to 60 Minutes</title>
          <description>Pain intensity is measured in numerical rating scale (NRS) units from 0 (&quot;no pain&quot;) to 10 (&quot;worst pain imaginable&quot;). The change here represents the NRS score given by the patients at 60 minutes subtracted from the score at baseline, before treatment in the Emergency Department.</description>
          <population>The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.
H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).
1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="3.1"/>
                    <measurement group_id="O2" value="5.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Reported no Pain or Mild Pain at 60 Minutes</title>
        <time_frame>60 minutes</time_frame>
        <population>The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.
H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).
1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)</population>
        <group_list>
          <group group_id="O1">
            <title>H2O (2 mg IV Hydromorphone)</title>
            <description>2 mg IV hydromorphone administered over 2-3 minutes as initial dose
H2O: 2 mg IV hydromorphone</description>
          </group>
          <group group_id="O2">
            <title>1+1 (1 mg IV Hydromorphone + Optional 1 mg IV Hydromorphone)</title>
            <description>1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the following question: &quot;Do you want more pain medication?&quot;
1+1: 1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reported no Pain or Mild Pain at 60 Minutes</title>
          <population>The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.
H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).
1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 minutes</time_frame>
      <desc>The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.
H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).
1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)</desc>
      <group_list>
        <group group_id="E1">
          <title>H2O (2 mg IV Hydromorphone)</title>
          <description>2 mg IV hydromorphone
H2O: 2 mg IV hydromorphone</description>
        </group>
        <group group_id="E2">
          <title>1+1 (1 mg IV Hydromorphone + Optional 1 mg IV Hydromorphone)</title>
          <description>1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the following question: &quot;Do you want more pain medication?&quot;
1+1: 1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers &quot;yes&quot; to the question, &quot;Do you want more pain medication?&quot;</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulse rate &lt;50 beats/min</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Administration of naloxone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>excludes patients who were nauseated or vomiting before receiving opioids</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>excludes patients who were nauseated or vomiting before receiving opioids in the ED</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation &lt;95%</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Systolic blood pressure &lt;90 mmHg</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew Chang</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-920-6626</phone>
      <email>achang3@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

